<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82392">
  <stage>Registered</stage>
  <submitdate>4/11/2007</submitdate>
  <approvaldate>9/11/2007</approvaldate>
  <actrnumber>ACTRN12607000577415</actrnumber>
  <trial_identification>
    <studytitle>EFFICACY AND SAFETY OF INTRAVITREAL AVASTIN IN EYES WITH NEOVASCULAR GLAUCOMA UNDERGOING AHMED GLAUCOMA VALVE IMPLANTATION</studytitle>
    <scientifictitle>EFFICACY AND SAFETY OF INTRAVITREAL AVASTIN IN EYES WITH NEOVASCULAR GLAUCOMA UNDERGOING AHMED GLAUCOMA VALVE IMPLANTATION</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>neovascular glaucoma</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The surgical procedure will consist of a 1-stage Ahmed Glaucoma Valve implantation using a standardized surgical technique. After administration of regional or general anesthesia, a fornix based conjunctival flap will be fashioned in the superotemporal quadrant. The anterior edge of the plate will be secured with 9-0 nylon sutures to the sclera at least 8 mm from the limbus. The tube tip will be cut obliquely to protect the tube lumen from the iris. A 23-gauge needle tract will be used to enter the anterior chamber through the limbus. The tube in the anterior chamber will be positioned anterior to the iris and away from the corneal endothelium. A donor sclera or a human pericardium patch graft will be fashioned from banked tissue and secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva will be sutured either with 8-0 or 9-0 polyglactin sutures or with 10-0 nylon sutures. The anterior chamber will be reformed with BSS through a paracentesis tract. Viscoelastic material will be injected into the anterior chamber at the surgeons discretion. At the end of surgery approximately 1.25 mg of bevacizumab (0.05 mL of commercially available bevacizumab at a concentration of 25 mg/mL) or 0.05 mL of sterille saline salt solution will be injected into the eye via pars plana with a 1.00-mL syringe attached to a 30-gauge needle.
The postoperative regimen will include a topical antibiotic and a cycloplegic for 2 to 4 weeks, and topical steroids for approximately 2 months. Antiglaucoma medication will be added as required to improve IOP reduction. Patients will be examined 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, and 18 months after surgery.</interventions>
    <comparator>Ahmed valve implant + placebo (0.05 mL of sterille saline salt solution)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Intraocular pressure control.
The measure will be done with Goldman applanation tonometer.</outcome>
      <timepoint>at six months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety of intravitreal bevacizumab in neovascular glaucoma</outcome>
      <timepoint>at six months after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients with uncontrolled neovascular glaucoma that underwent prior pan retinal photocoagulation requiring glaucoma drainage device implantation will be eligible.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients younger than 18 years; with learning difficulties, mental illness, or dementia; unconscious; or severely ill will not be included in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A computer program will generate the codes. A person who will not participate of data analysis will select the subjects.</concealment>
    <sequence>Computer program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>35</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>S?o Paulo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Enyr Saran Arcieri</primarysponsorname>
    <primarysponsoraddress>Av Getulio Vargas, 1700 - sl 4</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr. Enyr Saran Arcieri</fundingname>
      <fundingaddress>Av Getulio Vargas, 1700 - sl 4</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to evaluate the impact of the intravitreal bevacizumab injection on the Ahmed valve implant surgical outcome on neovascular glaucoma patients without clinical control. The design is a prospective, randomized, clinical trial with 35 individuals. Those individuals who need a drainage implant surgery to control the intraocular pressure (IOP), will be randomized for intravitreal 1.0 mg bevacizumab injection (0.04 mL of the commercial bevacizumad solution with a concentration of 25 mg/mL) or 0.5 mL of balanced salt solution. Surgical Success will be defined as the following criteria: (1) postoperative IOP equal or less than 21 mmHg; or (2) 30% IOP reduction or more after the surgery, with or without glaucoma medication. Any other situation will be considered surgical failure. Statistical analysis will be performed with the chi-square and t Students tests, the success rates will be compared with Kaplan-Meier curve and the log rank test.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica em Pesquisa - UNICAMP</ethicname>
      <ethicaddress>Rua Tessalia Vieira de Camargo, 126</ethicaddress>
      <ethicapprovaldate>24/07/2007</ethicapprovaldate>
      <hrec>0351.0.146.000-7</hrec>
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Enyr Saran Arcieri</name>
      <address>Av Getúlio Vargas, 1700 - sl 4</address>
      <phone>55-34-32912400</phone>
      <fax>55-34-32912400</fax>
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Enyr Saran Arcieri</name>
      <address>Av Getúlio Vargas, 1700 - sl 4</address>
      <phone>55-34-32912400</phone>
      <fax>55-34-32912400</fax>
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Enyr Saran Arcieri</name>
      <address>Av Getúlio Vargas, 1700 - sl 4</address>
      <phone>55-34-32912400</phone>
      <fax>55-34-32912400</fax>
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>